Invokana half-life is usually about 10 to 13 hours, so the amount of canagliflozin in the body falls by about half over that period. Most of the drug is cleared after several half-lives, which often means roughly 2 to 3 days rather than a few hours. That timing matters if you are asking about missed doses, side effects, surgery planning, kidney issues, or what may happen after the medicine is stopped.
Key Takeaways
- Label-based range: terminal half-life is about 10.6 to 13.1 hours.
- Typical clearance window: most of the drug is gone after about 4 to 5 half-lives.
- Different questions: half-life is not the same as duration of action.
- Main variables: kidney function, illness, hydration, and some interactions can change exposure.
- Stopping plans: any hold, stop, or restart should be reviewed with the prescriber.
Understanding Invokana Half-Life
Half-life describes how long it takes for a drug concentration to drop by about 50%. For canagliflozin, the generic name for Invokana, the official prescribing information reports an apparent terminal half-life of about 10.6 hours at one labeled dose and 13.1 hours at another. This is the figure most people mean when they ask how long the medicine stays in the system.
The phrase apparent terminal half-life sounds technical, but the idea is simple. After a tablet is absorbed, drug levels rise, peak, and then fall. The terminal phase is the later stretch of that decline. It helps estimate elimination, but it does not act like a personal stopwatch. Age, kidney function, illness, and other medicines can all shift the pattern.
When a once-daily medicine is taken regularly, one dose overlaps with the next. After several half-lives, the body reaches steady state, meaning the average exposure becomes fairly stable. The same process works in reverse after the drug is stopped. That is why half-life helps with expectations, even though it never replaces clinical context.
That is also why Invokana half-life does not equal the moment the drug stops working. A single half-life leaves about half the drug still present. After another half-life, about half of that remains. Drug levels fall in steps, not all at once.
| Term | What it means | Why it matters |
|---|---|---|
| Half-life | Time for blood levels to fall by about 50% | Helps estimate clearance speed |
| Terminal half-life | Late part of the elimination phase | Used for rough timing after a dose |
| Duration of action | How long the clinical effect may last | May not match one half-life exactly |
Why it matters: Blood-level timing, effect timing, and side-effect timing are related but not identical.
CanadianInsulin.com is a prescription referral platform, not a dispensing pharmacy.
When Is Most of the Drug Out of the Body?
A common rule of thumb is that a medicine is mostly cleared after about 4 to 5 half-lives. Using the published canagliflozin half-life range, that points to a rough window of about 2 to 3 days for most of the drug to leave the body. This is why the answer is usually measured in days, not just in hours.
If you do the math, five half-lives based on the label land a little over 2 days at the lower end and closer to 3 days at the higher end. That is the basis for the common estimate that most canagliflozin is out of the body within about 48 to 72 hours. It is still a rough estimate, not a promise for every patient.
It also helps to separate mathematical clearance from the body’s response. If the question is about extra urination, thirst, or a possible side effect, the answer may depend on what is happening with hydration, kidney function, or infection. If the question is about surgery or a planned hold, a clinician may use a safety buffer rather than the shortest possible elimination estimate.
Canagliflozin is metabolized mainly through glucuronidation and leaves the body through both urine and stool. That matters because clearance is shaped by more than one pathway. Example: two people can take the same medication and still clear it at different rates if one is dehydrated or has reduced kidney function. For broader context, the Type 2 Diabetes Category and the Type 2 Diabetes Hub organize related education and treatment topics.
What Changes Clearance and Exposure?
The biggest real-world variable is kidney function. Canagliflozin works at the kidney level by blocking sodium-glucose cotransporter 2, or SGLT2, which is a protein that helps the kidneys reabsorb glucose. Because the kidneys are central to both the drug’s action and its elimination profile, reduced kidney function can change exposure and can also affect how useful the drug is clinically.
Kidney function matters most
If kidney function is lower than expected, drug handling may become less predictable. That does not mean every person with kidney disease clears the medicine the same way, but it does mean a simple label estimate may not tell the full story. In practice, clinicians also think about recent lab values, fluid status, age, and why the medicine was prescribed in the first place.
Lower kidney function can also change the day-to-day experience of the drug. Because canagliflozin increases urinary glucose loss and can affect fluid balance, poor intake or active fluid loss can make the clinical picture more important than the pharmacology alone. That is one reason a care team may ask about vomiting, diarrhea, fever, dizziness, or reduced oral intake when reviewing this medicine.
Other factors can matter too
Acute illness, dehydration, and some drug interactions can all complicate the clearance question. Sometimes the interaction is direct, meaning another medicine may change canagliflozin exposure. Other times it is indirect, because a second drug may increase dehydration, lower blood pressure, or add kidney stress. The safest review usually starts with the full medication list rather than one drug in isolation.
If you are reviewing the wider condition and treatment landscape, the Diabetes Category and the Diabetes Hub can help place this medication within broader diabetes care.
When required, prescription details may be confirmed with the prescriber.
Half-Life Is Not the Same as How Long It Works
Canagliflozin lowers blood sugar by making the kidneys release more glucose into the urine. Because of that mechanism, the clinical effect does not map neatly onto a single number like the terminal half-life. A drug can be falling in the bloodstream while its daily physiologic effect is still noticeable, especially during regular once-daily use.
During regular use, each new dose is taken before the previous one is completely gone. That overlap helps create steady average exposure from day to day. It is one reason a once-daily schedule can work even though the half-life is shorter than 24 hours.
Invokana half-life is useful for estimating clearance, but it does not automatically tell you when every effect begins or ends. The answer differs from person to person. Someone asking about a missed dose has a different question than someone asking about a planned procedure, side effects, or when urine glucose should stop increasing.
That distinction matters for comparisons. A shorter half-life does not always mean a weaker medicine, and a longer half-life does not always mean a better one. Pharmacokinetics answer one question. Eligibility, kidney status, side effects, and treatment goals answer others.
It also helps to compare drug classes carefully. Other SGLT2 inhibitors, such as Farxiga Dapagliflozin and Jardiance, work through the same kidney-based pathway, but each product has its own label and pharmacokinetic profile. Other type 2 diabetes medicines, such as Metformin, work very differently. If you are comparing options across classes, the Diabetes Product Category is a browsing hub rather than a treatment recommendation.
What Happens When You Stop Taking It?
After you stop taking canagliflozin, blood levels decline over the next several half-lives, so most of the drug is usually out of the body within a few days. As the drug clears, the urine glucose effect fades and blood sugar control may shift back toward your underlying baseline. That change does not look the same in every person, especially if other diabetes medicines are still being used.
The reason for stopping matters. Some people ask because of common side effects. Others ask because of surgery, dehydration, infection, a new medical problem, or a medication change. In those situations, the relevant question may be less about the calendar and more about why the drug is being held and what monitoring is needed next.
For that reason, self-stopping can create confusion about whether a new symptom is from the drug leaving the body, the underlying diabetes, or the illness that triggered the stop. A medication review is often more useful than trying to calculate the exact last hour the drug was present.
Invokana half-life also does not predict how quickly every symptom will improve after stopping. If a side effect is tied to dehydration or infection, the body may need extra time to recover even after the medicine itself has largely cleared. If the medicine was contributing to increased urination, that effect may settle as levels fall, but the timeline still depends on the broader clinical picture.
Example: if someone pauses the medicine before a procedure, the key issue is often when eating, drinking, and kidney function return to a safer baseline, not just when the last tablet leaves the bloodstream.
Questions worth asking
- Reason for the hold: is this about illness, side effects, or a procedure?
- Kidney status review: have recent labs or dehydration changed the risk picture?
- Other medicines involved: are insulin, metformin, or diuretics part of the plan?
- Symptoms to watch: which changes matter over the next few days?
- Restart decision point: who decides if and when it is resumed?
Dispensing is handled by licensed third-party pharmacies where permitted.
When Faster Review or Medical Help Matters
Some symptoms deserve faster attention than a half-life calculation. Seek prompt medical guidance if there are signs of severe dehydration, fainting, trouble breathing, vomiting, confusion, severe abdominal pain, or symptoms that may fit ketoacidosis, which is a dangerous acid buildup in the blood. Serious urinary or genital infections, allergic reactions, and sudden worsening of kidney-related symptoms also need review.
This is also important when a planned surgery or acute illness is involved. SGLT2 inhibitors may need temporary holding in certain situations, but the exact plan should come from the prescribing clinician or surgical team. The key point is that timing decisions are driven by risk context, not by one number alone.
Even less dramatic symptoms can deserve review if they keep returning. Repeated dizziness, worsening thirst, urinary symptoms, or a noticeable change in blood sugar after stopping the drug are good reasons to contact the prescribing team. Do not wait for several half-lives to pass if the problem is getting worse.
Quick tip: Ask whether the question is about blood levels, duration of effect, or a reason to hold the medicine.
In short, Invokana half-life helps answer the timing question, but the practical answer still depends on kidney function, illness, and why you are asking. Further reading through the linked diabetes hubs can help place this medicine within broader type 2 diabetes care.
Authoritative Sources
- For label-based half-life data, see the FDA prescribing information for INVOKANA.
- For a clinician-focused drug summary, review the NCBI StatPearls overview of canagliflozin.
- For additional pharmacokinetic context, see the manufacturer medical summary of canagliflozin pharmacokinetics.
This content is for informational purposes only and is not a substitute for professional medical advice.
